Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 3

INFINITY PHARMACEUTICALS, INC.

Form 3

September 13, 2006

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

SECURITIESFiled pursuant to Section 16(a) of the Securities Exchange Act of 1934,

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement INFINITY PHARMACEUTICALS, INC. [INFI] A Burke Thomas Joseph (Month/Day/Year) 09/12/2006 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) C/O INFINITY (Check all applicable) PHARMACEUTICALS, INC.. 780 MEMORIAL 10% Owner Director **DRIVE** _X__ Officer Other (give title below) (specify below) (Street) 6. Individual or Joint/Group Assistant Treasurer Filing(Check Applicable Line) _X_ Form filed by One Reporting Person CAMBRIDGE, MAÂ 02139 Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 2. Amount of Securities 4. Nature of Indirect Beneficial 1. Title of Security Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect (Instr. 5) $D^{(1)}$ Â 0 No securities are beneficially owned Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
2. Date Exercisable and Securities Underlying Conversion Ownership Operivative Security

Expiration Date Securities Underlying Operivative Security

Derivative Security

3. Title and Amount of Securities Underlying Operivative Security

To Expiration Date Ownership Operivative Security

To Expiration Date Operivative Security

To Expiration Date Ownership Operivative Security

To Expiration Date Operivative Security

Expiration Date Operivative Security

To Expiration Date Operivative Securit

Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 3

(Instr. 4) Price of Derivative Derivative Security: Date **Expiration Title** Amount or Direct (D) Security Exercisable Date Number of or Indirect Shares (I) (Instr. 5)

Reporting Owners

Reporting Owner Name / Address

Director 10% Owner Officer Other

Burke Thomas Joseph

C/O INFINITY PHARMACEUTICALS, INC. 780 MEMORIAL DRIVE

CAMBRIDGE, MAÂ 02139

Signatures

/s/ Thomas J.

Burke

**Signature of Reporting Person

O9/13/2006

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2